Bifikafusp alfa

DB19185InvestigationalProtein Based Therapies

Bifikafusp alfa is under investigation in clinical trial NCT05329792 (L19IL2/L19TNF in Skin Cancer Patients).

Mechanism
Curator reviewed
Also known as
Darleukin · Daromun component L19IL2 · Immunoglobulin, anti-(human fibronectin ed-b domain) (synthetic human clone l19 scfv fragment) fusion protein with human interleukin 2 · L19-IL2 Monoclonal antibody-cytokine fusion protein
Code names
L19 - IL2

Resolves to

Compound
UNII2K7BN4G2DQCAS1957239-90-5
Clinical / RWD
ATCL01XY04
Targets
P02751FN1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
18Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 2 drug categories
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bifikafusp alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In